- Home
- ROIV
as 11-25-2025 1:27pm EST
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
| Founded: | 2014 | Country: | United Kingdom |
| Employees: | 750 | City: | LONDON |
| Market Cap: | 14.1B | IPO Year: | N/A |
| Target Price: | $21.19 | AVG Volume (30 days): | 8.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.54 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.73 - $21.35 | Next Earning Date: | 11-10-2025 |
| Revenue: | $20,329,000 | Revenue Growth: | -45.13% |
| Revenue Growth (this year): | -18.82% | Revenue Growth (next year): | 320.50% |
Stock Insider Trading Activity of Roivant Sciences Ltd. (ROIV)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Ramaswamy Vivek | ROIV | 10% Owner | Nov 17 '25 | Sell | $20.51 | 539,650 | $11,068,221.50 | 33,653,756 | |
| Ramaswamy Vivek | ROIV | 10% Owner | Nov 14 '25 | Sell | $20.33 | 1,027,670 | $20,892,531.10 | 33,653,756 | |
| Ramaswamy Vivek | ROIV | 10% Owner | Nov 13 '25 | Sell | $20.81 | 287,283 | $5,978,359.23 | 33,653,756 | |
| Venker Eric | ROIV | President & Immunovant CEO | Oct 13 '25 | Sell | $16.25 | 20,727 | $336,813.75 | 1,504,959 | |
| Venker Eric | ROIV | President & Immunovant CEO | Oct 9 '25 | Sell | $16.30 | 104,940 | $1,710,522.00 | 1,504,959 | |
| Venker Eric | ROIV | President & Immunovant CEO | Oct 8 '25 | Sell | $16.20 | 138,602 | $2,245,352.40 | 1,504,959 | |
| Venker Eric | ROIV | President & Immunovant CEO | Oct 7 '25 | Sell | $16.15 | 355,161 | $5,735,850.15 | 1,504,959 | |
| Venker Eric | ROIV | President & Immunovant CEO | Oct 6 '25 | Sell | $16.34 | 171,396 | $2,800,610.64 | 1,504,959 | |
| Venker Eric | ROIV | President & Immunovant CEO | Sep 23 '25 | Sell | $14.83 | 611,000 | $9,061,130.00 | 1,504,959 | |
| Venker Eric | ROIV | President & Immunovant CEO | Sep 22 '25 | Sell | $15.00 | 416,182 | $6,240,568.18 | 1,504,959 |
Latest Roivant Sciences Ltd. News
ROIV Breaking Stock News: Dive into ROIV Ticker-Specific Updates for Smart Investing
MT Newswires
a day ago
Roivant Sciences Insider Sold Shares Worth $26,304,500, According to a Recent SEC Filing
Zacks
19 days ago
Urogen Pharma (URGN) Reports Q3 Loss, Misses Revenue Estimates
Zacks
20 days ago
LENZ Therapeutics, Inc. (LENZ) Reports Q3 Loss, Beats Revenue Estimates
Insider Monkey
21 days ago
Do You Believe in the Growth Prospects of Roivant Sciences Ltd. (ROIV)?
Insider Monkey
2 months ago
Roivant’s Brepocitinib Phase 3 Dermatomyositis Trial Hits Primary and All Key Secondary Endpoints
Simply Wall St.
2 months ago
Why Analysts Are Rethinking Roivant Sciences After Strong Phase 3 Results and Analyst Upgrades
Benzinga
2 months ago
Vivek Ramaswamy's Bitcoin Play Just Got Bigger: This $1.3B Deal Could Signal Corporate Crypto's Next Phase
Reuters
2 months ago
Ramaswamy-backed Strive to buy Semler in $1.3 billion deal all stock deal, boosting Bitcoin holdings
Compare ROIV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ROIV Roivant Sciences Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.